KRAS and colorectal carcinoma: Finally, we demonstrated that targeting downstream signaling of SLC25A22 via SRC inhibitor (Fig. S15) or ASNase (Fig. S15) potentiated the effectiveness of anti-PD1 in inhibiting the growth of MC38-KrasG12V allografts, in agreement with the SLC25A22-asparaingine-SRC axis as a therapeutic target for overcoming immunotherapy resistance in KRAS-mutant CRC.